Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Autor: Hui, R. ^*, Garon, E.B., Goldman, J.W., Leighl, N.B., Hellmann, M.D., Patnaik, A., Gandhi, L., Eder, J.P., Ahn, M.-J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G.M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N.A.

Publikováno v: In Annals of Oncology April 2017 28(4):874-881

Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer:Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Autor: Coleman, R.L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Rangwala, R., Vindeløv, S.D., Chen, M., Harris, J.R., Nicacio, L., Teng, M.S.L., Smith, M., Monk, B.J., Vergote, I.B.

Publikováno v: Coleman, R L, Lorusso, D, Gennigens, C, González-Martín, A, Randall, L, Cibula, D, Lund, B, Woelber, L, Pignata, S, Forget, F, Redondo, A, Rangwala, R, Vindeløv, S D, Chen, M, Harris, J R, Nicacio, L, Teng, M S L, Smith, M, Monk, B J & Vergote, I B 2020, ' Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer : Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study ', Annals of Oncology, vol. 31, no. Suppl. 4, pp. S1162-S1163 . https://doi.org/10.1016/j.annonc.2020.08.2262

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3907c117279139277496a33567601149
https://vbn.aau.dk/da/publications/6db43e87-ed42-4cd6-a2e0-fdae9e137349

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Autor: Coleman, R.L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Rangwala, R., Vindeløv, S.D., Chen, M., Harris, J.R., Nicacio, L., Teng, M.S.L., Smith, M., Monk, B.J., Vergote, I.B.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S1162-S1163

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LBA8_PR - KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Autor: Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M., Lubiniecki, G.M., Shentu, Y., Rangwala, R., Brahmer, J.R.

Publikováno v: In Annals of Oncology 1 October 2016 27 Supplement 6:vi578-vi578